Cargando…

Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications

BACKGROUND/OBJECTIVE: We retrospectively analyzed the effective and safety of continuous low-dose cyclophosphamide combined with prednisone (CP) in relapsed and refractory multiple myeloma (RRMM) patients with severe complications. METHODS: A total of 130 RRMM patients with severe complications were...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Haotian, Wei, Wei, Peng, Rong, Chen, Haimin, Zhou, Nian, Wu, Lixia, Yu, Wenjun, Zhao, Wenhao, Hou, Jian, Zhou, Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240086/
https://www.ncbi.nlm.nih.gov/pubmed/37284198
http://dx.doi.org/10.3389/fonc.2023.1185991
_version_ 1785053667156557824
author Shi, Haotian
Wei, Wei
Peng, Rong
Chen, Haimin
Zhou, Nian
Wu, Lixia
Yu, Wenjun
Zhao, Wenhao
Hou, Jian
Zhou, Fan
author_facet Shi, Haotian
Wei, Wei
Peng, Rong
Chen, Haimin
Zhou, Nian
Wu, Lixia
Yu, Wenjun
Zhao, Wenhao
Hou, Jian
Zhou, Fan
author_sort Shi, Haotian
collection PubMed
description BACKGROUND/OBJECTIVE: We retrospectively analyzed the effective and safety of continuous low-dose cyclophosphamide combined with prednisone (CP) in relapsed and refractory multiple myeloma (RRMM) patients with severe complications. METHODS: A total of 130 RRMM patients with severe complications were enrolled in this study, among which 41 patients were further given bortezomib, lenalidomide, thalidomide or ixazomib on the basis of CP regimen (CP+X group). The response to therapy, adverse events (AEs), overall survival (OS) and progression-free survival (PFS) were recorded. RESULTS: Among the 130 patients, 128 patients received therapeutic response assessment, with a complete remission rate (CRR) and objective response rate (ORR) of 4.7% and 58.6%, respectively. The median OS and PFS time were (38.0 ± 3.6) and (22.9±5.2) months, respectively. The most common AEs were hyperglycemia (7.7%), pneumonia (6.2%) and Cushing’s syndrome (5.4%). In addition, we found the pro-BNP/BNP level was obviously decreased while the LVEF (left ventricular ejection fraction) was increased in RRMM patients following CP treatment as compared with those before treatment. Furthermore, CP+X regimen further improved the CRR compared with that before receiving the CP+X regimen (24.4% vs. 2.4%, P=0.007). Also, both the OS and PFS rates were significantly elevated in patients received CP+X regimen following CP regimen as compared with the patients received CP regimen only. CONCLUSION: This study demonstrates the metronomic chemotherapy regimen of CP is effective to RRMM patients with severe complications.
format Online
Article
Text
id pubmed-10240086
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102400862023-06-06 Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications Shi, Haotian Wei, Wei Peng, Rong Chen, Haimin Zhou, Nian Wu, Lixia Yu, Wenjun Zhao, Wenhao Hou, Jian Zhou, Fan Front Oncol Oncology BACKGROUND/OBJECTIVE: We retrospectively analyzed the effective and safety of continuous low-dose cyclophosphamide combined with prednisone (CP) in relapsed and refractory multiple myeloma (RRMM) patients with severe complications. METHODS: A total of 130 RRMM patients with severe complications were enrolled in this study, among which 41 patients were further given bortezomib, lenalidomide, thalidomide or ixazomib on the basis of CP regimen (CP+X group). The response to therapy, adverse events (AEs), overall survival (OS) and progression-free survival (PFS) were recorded. RESULTS: Among the 130 patients, 128 patients received therapeutic response assessment, with a complete remission rate (CRR) and objective response rate (ORR) of 4.7% and 58.6%, respectively. The median OS and PFS time were (38.0 ± 3.6) and (22.9±5.2) months, respectively. The most common AEs were hyperglycemia (7.7%), pneumonia (6.2%) and Cushing’s syndrome (5.4%). In addition, we found the pro-BNP/BNP level was obviously decreased while the LVEF (left ventricular ejection fraction) was increased in RRMM patients following CP treatment as compared with those before treatment. Furthermore, CP+X regimen further improved the CRR compared with that before receiving the CP+X regimen (24.4% vs. 2.4%, P=0.007). Also, both the OS and PFS rates were significantly elevated in patients received CP+X regimen following CP regimen as compared with the patients received CP regimen only. CONCLUSION: This study demonstrates the metronomic chemotherapy regimen of CP is effective to RRMM patients with severe complications. Frontiers Media S.A. 2023-05-22 /pmc/articles/PMC10240086/ /pubmed/37284198 http://dx.doi.org/10.3389/fonc.2023.1185991 Text en Copyright © 2023 Shi, Wei, Peng, Chen, Zhou, Wu, Yu, Zhao, Hou and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Shi, Haotian
Wei, Wei
Peng, Rong
Chen, Haimin
Zhou, Nian
Wu, Lixia
Yu, Wenjun
Zhao, Wenhao
Hou, Jian
Zhou, Fan
Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications
title Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications
title_full Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications
title_fullStr Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications
title_full_unstemmed Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications
title_short Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications
title_sort continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240086/
https://www.ncbi.nlm.nih.gov/pubmed/37284198
http://dx.doi.org/10.3389/fonc.2023.1185991
work_keys_str_mv AT shihaotian continuouslowdosecyclophosphamideplusprednisoneinthetreatmentofrelapsedandrefractorymultiplemyelomawithseverecomplications
AT weiwei continuouslowdosecyclophosphamideplusprednisoneinthetreatmentofrelapsedandrefractorymultiplemyelomawithseverecomplications
AT pengrong continuouslowdosecyclophosphamideplusprednisoneinthetreatmentofrelapsedandrefractorymultiplemyelomawithseverecomplications
AT chenhaimin continuouslowdosecyclophosphamideplusprednisoneinthetreatmentofrelapsedandrefractorymultiplemyelomawithseverecomplications
AT zhounian continuouslowdosecyclophosphamideplusprednisoneinthetreatmentofrelapsedandrefractorymultiplemyelomawithseverecomplications
AT wulixia continuouslowdosecyclophosphamideplusprednisoneinthetreatmentofrelapsedandrefractorymultiplemyelomawithseverecomplications
AT yuwenjun continuouslowdosecyclophosphamideplusprednisoneinthetreatmentofrelapsedandrefractorymultiplemyelomawithseverecomplications
AT zhaowenhao continuouslowdosecyclophosphamideplusprednisoneinthetreatmentofrelapsedandrefractorymultiplemyelomawithseverecomplications
AT houjian continuouslowdosecyclophosphamideplusprednisoneinthetreatmentofrelapsedandrefractorymultiplemyelomawithseverecomplications
AT zhoufan continuouslowdosecyclophosphamideplusprednisoneinthetreatmentofrelapsedandrefractorymultiplemyelomawithseverecomplications